
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics
SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains its drug development strategy to combat important global viral threats.
Measles outbreaks have continued to expand in the US, and the dramatic ten-fold increase in annual Measles cases in Europe last year indicates that Measles will be here to stay. Measles vaccine failure cases have also been increasing according to the European data, which is an important cause for concern. Vaccination rates are falling in developed countries.
In this global scenario, NV-387, the clinical stage broad-spectrum, host-mimetic antiviral nanomedicine drug could perhaps be the only currently available drug candidate to combat the Measles virus and disease. There is no approved drug for Measles virus infection.
The Company has already initiated the process for conducting an animal efficacy study that would provide an answer to how effective NV-387 would be against Measles virus.
The Company will make NV-387 available to any licensed physicians intending to treat Measles cases under the Individual Patient Expanded Access protocol of the US FDA. The Company has its own cGMP manufacturing facility.
The Company is pleased to state that it is moving forward with the Phase II Clinical Trial Application (CTA) for the evaluation of NV-387 as treatment of MPox in the Domestic Republic of Congo (DRC). The National Ethics Committee of DRC has recently cleared NV-387 as a potential drug candidate that should advance into the clinical trial, enabling the CTA.
MPox is endemic in DRC, and has continued to cause large numbers of cases in the WHO African Region. In April, 2025, the WHO has restated that MPox continues to be a Public Health Emergency of International Concern (PHEIC), a designation it first declared for the MPox epidemic in August, 2024.
This PHEIC is driven by MPox Clade 1a and 1b viruses that are highly pathogenic and highly transmissible. A milder version, MPox Clade 2, caused an epidemic in 2022, and since then became endemic, in certain subsets of populations in the Western World. It is thought that MPox Clade 1a/1b viruses could possibly lead to a wider epidemic including the rest of the world beyond Africa.
There is currently no approved drug for the treatment of MPox infection. A drug, tecovirimat, (TPOXX®, SIGA) failed in clinical trials for the treatment of MPox. TPOXX has been approved for Smallpox in the USA under the FDA "Animal Rule" and continues to be stockpiled by the US Strategic National Stockpile. A broad-spectrum antiviral effective against all orthopoxviruses including MPox and Smallpox is needed.
"NV-387 is a revolutionary antiviral drug that can combat many viral infections," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, "We are advancing it rapidly towards establishing human clinical effectiveness data and regulatory approvals. We believe our MPox and Measles work will enable rapid advancement of the drug, and make a great global impact in large markets fulfilling unmet medical needs."
The Company is also developing NV-387 as an "emperic" treatment of respiratory viral infections. We are developing a clinical protocol for a "basket-type" clinical trial, i.e. evaluating a single drug, namely, NV-387, against many viruses within a single clinical trial.
The focus of this proposed clinical trial will be on All Influenzas, All Coronaviruses, and RSV. If successful, this study would enable NV-387 to be prescribed immediately when a patient presents to the physician with a respiratory infection suspected to be viral, without waiting for test results to determine which viral infection it is.
Additionally, the Company is developing a pan-herpesvirus drug, NV-HHV-1. Herpesvirus infections from HSV-1, HSV-2, VZV, EBV, as well as HHV-6 have been linked to neurological damage that can eventually lead to Alzheimer's disease. An effective drug that can eradicate herpesviruses is an unmet medical need. Such a drug can make a major impact on chronic diseases such as Alzheimer's.
To date, only effective drugs have brought or maintained endemic or circulating viruses under control. There are no vaccines for herpes viruses, HIV or hepatitis C virus. Yet, successful drugs have helped patients to be cured (HCV), or recover from episodes (HSV), or at least maintain healthy lifespan (HIV) without any vaccines.
Market sizes for effective antiviral drugs run into several billions of dollars for each indication. Also, market sizes expand rapidly once an effective drug is introduced.
"NanoViricides is poised to revolutionize how we treat viral infections, just as antibiotics revolutionized treatment of bacterial infections," said Dr. Diwan, adding, "We continue to march forward and strive hard to make this bright future a reality and to make a meaningful impact on public health, chronic diseases, and individual patients."
Measles confirmed cases in the US have surpassed 1,000 already as of May 8th, 2025, across 31 jurisdictions, according to CDC report (https://www.cdc.gov/measles/data-research/index.html) .
Measles cases in Europe were over 35,000 in 2024, an almost ten-fold increase from 2023, according to the annual report of European Center for Disease Prevention and Control (ECDC). Only approximately 87% of cases were in unvaccinated persons, and 13% of the cases were of vaccine failure, out of the cases with known vaccination status.
The significant Measles vaccine failure rate observed in Europe is alarming, considering that the two-dose vaccine is supposed to be 97% effective. Overall, childhood vaccination was about 94% and declining. This rate is below the 95% considered the threshold for achieving "herd" or community immunity.
Given the various causes of vaccine failure, and of vaccine hesitancy, attaining 95% vaccine coverage cannot be considered a very probable solution to combating the Measles epidemic. An effective drug is needed to combat the epidemic.
ABOUT NANOVIRICIDES
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:NanoViricides, Inc.info@nanoviricides.com
Public Relations Contact:ir@nanoviricides.com
SOURCE: NanoViricides, Inc.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
CS Analytical to Serve as Bronze Level Sponsor Contract Pharma 2025 Contracting & Outsourcing Conference
This conference will provide the CS Analytical Team to meet many current and potential clients and will grant us an opportunity to review many of the unique services we bring to the marketplace when it comes to container and package regulatory qualification. CLIFTON, N.J., June 9, 2025 /PRNewswire/ -- CS Analytical Laboratory, the world's only cGMP, FDA-registered and inspected contract laboratory exclusively designed and dedicated to package and container testing for the pharmaceutical, biotechnology, and medical device industries is excited to announce that it will serve as Bronze Level Sponsor for the 2025 Contract Pharma Contracting and Outsourcing Conference to be held on September 18-19th at the Hyatt Regency in New Brunswick, New Jersey. The two-day conference and one-day exhibition provides the perfect venue for easy and informal discussions for manufacturing, packaging and laboratory services. The tabletop exhibit hall will be open on Thursday September 18th with conference programming taking place on both Thursday and Friday. To register to attend the conference please use the following link: "The CS Analytical Team is excited to serve as a Bronze Level Sponsor and to be participating in the conference," commented CS Analytical Chief Operations Officer Brandon Zurawlow. "This conference will provide the CS Analytical Team an opportunity to meet many current and potential clients and will grant us an opportunity to review many of the unique services we bring to the marketplace when it comes to container and package regulatory qualification." The CS Analytical Team will be highlighting key service areas to include USP 1207 Container Closure Integrity Testing for IV Bag Package Systems and ISTA / ASTM Distribution testing for unique live cell-based therapy package systems. With the recent installation of a suite of highly advanced instruments, CS Analytical now offers clients a platform to test their product package system through a variety of concurrent environmental stressors to include pressure, vibration and temperature. No other service provider has this capability. Please contact us at engage@ if you have any questions. About CS Analytical Laboratory The world's only cGMP, FDA-registered contract laboratory exclusively designed and dedicated to container testing for the pharmaceutical, biotechnology, and medical device industries, the CS Analytical Team includes world-leading experts and thought-leaders on FDA and EU regulatory expectations and USP and EP primary package testing requirements inclusive of container closure integrity (CCI) testing (CCIT). Test services include CCI method development, validation, and analysis, USP/EP/JP physical and physicochemical testing, and Comprehensive and Complementary services for all common or unique primary packaging components and systems inclusive of glass, plastic, elastomeric, and more. CS Analytical is the single source to ensure a regulated industry product-package system meets strict, complex, and ever-changing regulatory requirements. About Contract PharmaContract Pharma is the premier media outlet linking contract service providers and their pharma/biopharma sponsors. Rooted in our legacy print publication—issued 9 times per year—the Contract Pharma brand continues to evolve across its digital media platforms through and social media channels. Contract Pharma offers a wide variety of products designed to maximize brand exposure and get your message across to the companies and decision makers that matter most. View original content to download multimedia: SOURCE CS Analytical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Viemed Healthcare Announces Share Repurchase Program
LAFAYETTE, La., June 09, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the 'Company' or 'Viemed') (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that its Board of Directors has authorized a share repurchase program, effective through June 2026. Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the Company ('the Common Shares') from time to time in accordance with applicable securities laws, representing approximately 5% of the total issued and outstanding Common Shares as of March 31, 2025. The Company intends to repurchase Common Shares through open market purchases, block purchases or otherwise in accordance with applicable securities laws. Subject to certain exceptions for block purchases, daily purchases will be limited to 25% of the average daily volume for the four calendar weeks preceding the date of purchase. Casey Hoyt, Viemed's Chief Executive Officer, noted, 'Our recent first quarter 2025 results and the increases in our 2025 guidance range midpoints demonstrate that we are executing well with strong underlying fundamentals in the business. We have a track record of disciplined capital allocation, with our latest example being the attractive acquisition of Lehan's Medical that is expected to close in the third quarter of this year. Since our public listing, we have repurchased approximately 2.6 million shares, underscoring our commitment to executing on our capital allocation strategies. With no net debt and full availability on our $55 million credit facility, we have ample liquidity to improve shareholder value with a new share repurchase program while also funding our organic and inorganic growth initiatives.' The price paid for the Common Shares will be the market price at the time of purchase, plus applicable brokerage fees, or such other prices as may be permitted by applicable securities laws. There can be no assurance as to the precise number of Common Shares that will be repurchased under the program, if any. The Company may discontinue its purchases at any time, subject to compliance with applicable securities laws. The Common Shares purchased by the Company will be cancelled. ABOUT VIEMED HEALTHCARE, INC. Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at statements contained in this press release may constitute 'forward-looking statements' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or 'forward-looking information' as such term is defined in applicable Canadian securities legislation (collectively, 'forward-looking statements'). Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'expects', 'is expected', 'budget', 'potential', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', 'believes', 'projects', or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results 'will', 'should', 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved' or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's expectations regarding the amount and timing of any potential repurchases of Common Shares, the funding sources for such repurchases, the availability of Common Shares for such repurchases, and the anticipated benefits to shareholders of such repurchases, as well as about its pending acquisition of Lehan's Medical Equipment, such as expected purchase price, contingent payments, closing date, funding sources, and anticipated synergies and other benefits are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the 'SEC') available on the SEC's website at including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law. For further information, please contact: Investor Relationsir@ Tripp SullivanSCR Partners, LLC615-942-7077 Trae FitzgeraldChief Financial OfficerViemed Healthcare, Inc.337-504-3802
Yahoo
39 minutes ago
- Yahoo
Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing
NEWPORT NEWS, Va., June 9, 2025 /PRNewswire/ -- Dilon Technologies®, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, today announced a $9 million growth capital investment from JGB Management Inc. The investment will support Dilon's continued double-digit revenue growth and operational scaling. Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes. "We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide," said George Makhoul, CEO of Dilon Technologies. "This funding empowers us to continue delivering best-in-class innovations that improve patient care." HEMOBLAST Bellows® is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST® Bellows continues to redefine standards in surgical hemostasis. Another key product, MarginProbe® an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe® reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end. Dilon's Navigator™ Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025. "We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide," said Brett Cohen, CEO of JGB Management Inc. For more information, visit About Dilon Technologies® Technologies® Inc. is a commercial-stage medical device company that develops, manufactures, and markets innovative technologies used in hemostasis, cancer detection and assessment, and airway management. Dilon's growing surgical portfolio includes: HEMOBLAST Bellows®: The only FDA-approved powder-form hemostatic agent for minimal, mild, and moderate bleeding. MarginProbe®: A groundbreaking real-time margin assessment tool for breast cancer surgery. Navigator™ System: A leading surgical gamma probe for tumor localization and lymphatic mapping. TrueView 100 Pro: A surgical specimen analyzer for intraoperative use. CoPilot VL+®: A compact, portable video laryngoscope for airway visualization. About JGB Management Inc. JGB Management Inc., founded by Brett Cohen in 2005, is an alternative asset management firm focused on investing in niche credit-oriented situations. JGB specializes in privately negotiated investments. The firm is based in Westport CT. View original content to download multimedia: SOURCE Dilon Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data